Current Clinical Trials

Neuropathic Pain
(LAT-NP-001)


Lateral Pharma commenced its first clinical study, LAT-NP-001, in Q1 2019.


Read More

Acute migraine (LAT-MIG-001)


Lateral Pharma commenced its second clinical study, LAT-MIG-001, in Q3 2019.


Read More

Safety


The preclinical and clinical data with LAT8881 available to date do not suggest any significant safety concerns. There are no established SAEs associated with administration of LAT8881, and no pattern of severe, related AEs.


Read more

Subscribe now!